iSERA Lifesciences updates preferential issue disclosures 2026

What changed in the latest filings

iSERA Lifesciences Ltd (BSE: 534920) disclosed shareholder approval for amendments to disclosures linked to its proposed preferential issue. The company said the changes were approved through a re-opened remote e-voting process conducted between June 27 and June 29, 2026. According to the update, the amendments addressed a typographical error in the number of shares proposed to be allotted to a promoter-director and replaced a general post-issue statement with detailed, person-wise holdings. The company noted that the underlying preferential issue resolution had already been passed by members earlier, and this vote was to confirm the disclosure amendments. The corrigendum was issued after BSE queries under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Re-opened e-voting: dates, participation, and outcome

The re-opened e-voting window ran from June 27, 2026 to June 29, 2026, following a corrigendum dated June 26, 2026. iSERA Lifesciences reported that the resolutions were passed with 100% of the valid votes cast. A total of 13 members participated in the process. The company disclosed that 553,230 valid votes were cast in favour of both resolutions and that no votes were cast against them. The narrative indicates the process was undertaken to align the disclosures with regulatory expectations after exchange-level queries.

The typo correction: promoter allotment details

One of the resolutions approved the correction of a typographical error related to the proposed allotment to Dhairyasheel Vasantrao Yadav, identified as Promoter and Director. The filing corrected the entry from “4,50,50” to 4,50,500 equity shares. The company also disclosed his pre-issue shareholding as 11,15,000 shares. iSERA Lifesciences stated the preferential issue resolution itself had been passed by members on May 21, 2026, and the June re-vote was limited to amendments in the explanatory statement and related disclosures. This update is relevant because the number of shares directly affects post-issue ownership calculations.

Why post-issue shareholding disclosures were expanded

The second resolution replaced a general post-issue capital statement with a detailed person-wise disclosure of the percentage of post-preferential issue capital to be held by each allottee. The company said the revised disclosure confirms that existing promoters will continue to be the promoters and that there will be no change in management or control. In its document excerpt, iSERA Lifesciences shared a table of allottees and corresponding percentages, with examples including Shubhangi Dhanraj Garad (14.46%), Sumeet Dhanraj Garad (5.25%), Pratap Dadasaheb Deshmukh (5.43%), Ritu Dhanraj Garad (3.44%), Archana Kakasaheb Lonkar (4.86%), Nandkumar Subhash Kadam (6.39%), and Dhairyasheel Vasant Rao Yadav (6.37%). It also listed fund entities such as Nav Capital VCC - Nav Capital Emerging Star Fund (4.07%), M7 Global Fund PCC - Cell Dewcap Fund (1.73%), and Dovetail Global Fund PCC All Seasons India Opportunities Fund (0.61%).

Link to the share-swap acquisition of iSERA Biological

The company’s preferential issue is tied to a proposed acquisition via consideration other than cash, specifically a share swap. iSERA Lifesciences disclosed that its Board had considered and approved acquiring equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited (unlisted public company, CIN: U85300PN2016PLC165483). The acquisition covers up to 1,61,82,800 equity shares of face value Rs. 10 each. The total consideration mentioned was Rs. 78,00,10,960, to be discharged entirely by issuing and allotting up to 1,61,82,800 fully paid-up equity shares of iSERA Lifesciences. The company also referenced shareholder approval for the related party transaction associated with the acquisition.

Authorised capital increase approved by the board

In the same regulatory context, iSERA Lifesciences disclosed that its Board considered and approved increasing the authorised share capital. The authorised capital was proposed to increase from Rs. 11,00,00,000, divided into 1,10,00,000 equity shares of Rs. 10 each, to Rs. 25,00,00,000, divided into 2,50,00,000 equity shares of Rs. 10 each. This increase includes creation of 1,40,00,000 additional equity shares of Rs. 10 each. The stated reason within the broader set of approvals aligns with enabling corporate actions connected to the share swap and associated issuance.

Other equity allotments cited in the disclosures

Separately, the document text also references an allotment connected to an approved Resolution Plan. It states that 3,00,000 equity shares were allotted to Mr. Ganapa Narsi Reddy on a preferential basis, resulting in his post-allotment shareholding comprising 92.75% of the total issued and subscribed equity share capital of the company. The material also includes a rights issue data point for the year ended March 31, 2026. During the year, iSERA Lifesciences allotted 80,85,550 equity shares of face value Rs. 10 each at par, aggregating to Rs. 8,08,55,500, in a ratio of 25 equity shares for every 1 fully paid-up equity share held. The company also reported net profit of Rs. 25.94 lakh for the year ended March 31, 2026, compared with Rs. 11.81 lakh in the prior year.

Key facts table

Market impact: what investors can take from the update

The disclosures primarily change the clarity of the preferential issue documentation rather than introducing a new transaction. For investors, the key takeaway is that the company has confirmed person-wise post-issue holdings and corrected the share count error that could have affected ownership percentages. The company also reiterated that it expects no change in management or control following the preferential issue. The proposed share swap acquisition provides a quantified reference point for the transaction structure, including the consideration value (Rs. 78,00,10,960) and the maximum number of shares to be issued (up to 1,61,82,800). Separately, the FY26 rights issue and reported profit numbers provide context on recent capital-raising activity and profitability, but the filing does not provide stock price reaction or valuation commentary.

Conclusion

iSERA Lifesciences’ latest update formalises corrections and expanded disclosures for its preferential issue, backed by 100% approval in the re-opened e-voting process. The clarified disclosures sit alongside the company’s share-swap plan to acquire up to 100% of iSERA Biological and the authorised capital increase meant to support such issuance. Next, investors will track subsequent regulatory filings and any further corporate actions required to execute the preferential issue and the acquisition as approved.